This is a working overview of alpha-MSH, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-05 and is reviewed periodically as new material appears.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
On January 1, 1899, after the United States defeated Spain at the end of the Spanish–American War and claimed Cuba as the Military Government of Cuba, Spaniards and the Spanish military left the islands of Cuba returning to mainland Spain, and any major influence of the Grand Lodge of Spain was taken with them. Both of the American Military Governors of Cuba, John R. Brooke and Leonard Wood, were high-ranking Freemasons, as was the President of the United States, William McKinley. On the same day that the Spanish left, on January 1, individual Lodges across Cuba began meeting again regularly. Padilla Lodge was able to purchase an old industrial warehouse in Havana. A mass immigration of US citizens to Cuba brought with it much closer coordination with the mainland American Lodges, and many of the highest-ranking US military government officials took a stance of cooperation with the Lodges in Cuba in order to completely restructure the Cuban Freemasonic system and purge it of Spanish aristocratic influence. These high-ranking officials included Admiral Schley, General Shafter, General Scott, Colonel Theodore Roosevelt and General George M. Moulton.
== Methods of antibody elution == There are several methods of antibody elution used in clinical blood banking. Some of these methods include manipulating temperature, manipulating pH, use of organic solvents, and chloroquine. Each of these methods have advantages and disadvantages, and the method of elution will vary depending on clinical utility. One of the more commonly used methods is an acid elution, because it is quick, cheap, and relatively easy to perform.
== Chemistry == Atenolol is a substituted phenethylamine derivative. It is specifically β-phenylethylamine with an α-keto substitution and a 4- substitution on the phenyl ring. The experimental log P of atenolol is 0.16 and its predicted log P ranges from −0.03 to 0.57. Atenolol showed the lowest predicted lipophilicity of 30 clinically relevant beta blockers.
Sources: en.wikipedia.org
== Reliability == Across diverse conditions, researchers report relatively satisfactory reliability estimates for scores on the 14- and 10-item forms. For example, Roberti et al. (2006) reported reliability estimates of .85 and .82 in a university sample for scores on the perceived helplessness and perceived self-efficacy scales, respectively. Highly similar results were reported in Taylor (2015) in a sample of middle-aged adults. However, one of the limitations for much of the reliability estimates reported in the extant literature is the overly restrictive requirement of tau-equivalence for accurate reliability estimates. Tau-equivalence requires each item of a scale to have approximately the same size of relationship with the unobserved characteristic (e.g., perceived self-efficacy) driving responses to the items as well as consistent reliability regardless of the latent level driving the responses to the items. Therefore, it is largely unknown whether items on the PSS assign scores with the same degree of reliability for respondents with high latent levels (e.g., perceived helplessness) as respondents with low latent levels. One exception is in Taylor (2015), where the graded response model was utilized to study the reliability levels across levels of the two latent variables.
Another suggests that StAR acts in conjunction with PBR, causing the movement of Cl− out of the mitochondria to facilitate contact site formation. However, evidence for an interaction between StAR and PBR remains elusive.
When initially discovered, some scientists proposed that Osedax was a whale-bone specialist, a notion later disproven by the discovery of Osedax on a variety of skeletal substrates including bone fragments, teleost bones, shark teeth, reptile and bird skeletons, pinniped bones, experimentally placed cow bones, and even human remains. Multiple species of Osedax can co-exist in close proximity, even on the same bone. Osedax and their borings enhance local biodiversity by dissolving the tough external cortical bone and tunneling through their internal layers, increasing structural complexity and providing new regions for microfauna to colonize. As such, Osedax are considered ecosystem engineers. However, these borings compromise the structural integrity of the bones, causing them to collapse after extensive boring, rendering these new habitats temporary. The role of Osedax in the degradation of marine vertebrate remains is important to marine vertebrate taphonomy.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
The dry powder is more stable during transport and storage than a solution. It also allows a known amount of material to be reconstituted at a chosen concentration.